FRI0239 Decreased prevalence of anxiety and depression in rheumatoid arthritis patients following b cell-targeted biologic therapy

Гайсин, И. Р.; Иванова, Л. А.

doi:10.1136/annrheumdis-2013-eular.1366

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is evidence of reductions in depressive symptoms due to antirheumatic treatment. For example, depression levels decreased significantly following commencement and continuity of rituximab, a B cell-directed therapy, among individuals with RA [199]. Therefore, future studies need to systematically evaluate whether antirheumatic treatment among individuals with RA can help alleviate depressive symptoms.…”

Section: Expert Commentarymentioning

confidence: 99%

Healthcare burden of depression in adults with arthritis

Sambamoorthi

Shah

Zhao

2017

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Introduction Arthritis and depression are two of the top disabling conditions. When arthritis and depression exist in the same individual, they can interact with each other negatively and pose a significant healthcare burden on the patients, their families, payers, healthcare systems, and society as a whole. Areas covered The primary objective of this review is to summarize, identify knowledge gaps and discuss the challenges in estimating the healthcare burden of depression among individuals with arthritis. Electronic literature searches were performed on PubMed, Embase, EBSCOhost, Scopus, the Cochrane Library, and Google Scholar to identify relevant studies. Expert Commentary Our review revealed that the prevalence of depression varied depending on the definition of depression, type of arthritis, tools and threshold points used to identify depression, and the country of residence. Depression exacerbated arthritis-related complications as well as pain and was associated with poor health-related quality of life, disability, mortality, and high financial burden. There were significant knowledge gaps in estimates of incident depression rates, depression attributable disability, and healthcare utilization, direct and indirect healthcare costs among individuals with arthritis.

show abstract

Section: Expert Commentarymentioning

confidence: 99%

Healthcare burden of depression in adults with arthritis

Sambamoorthi

Shah

Zhao

2017

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

“…There is some evidence that disease-modifying drugs used to treat RA can have spill-over effects in reducing depressive symptoms. For example, depression levels decreased significantly following commencement and continuity of rituximab, a B cell-directed therapy, among individuals with RA [ 29 ]. Therefore, future studies need to systematically evaluate whether antirheumatic treatment among individuals with RA can help alleviate depressive symptoms.…”

Section: Discussionmentioning

confidence: 99%

Burden of Depression among Working-Age Adults with Rheumatoid Arthritis

et al. 2018

View full text Add to dashboard Cite

Objective This study estimated the excess clinical, humanistic, and economic burden associated with depression among working-age adults with Rheumatoid Arthritis (RA). Methods A retrospective cross-sectional study was conducted among working-age (18 to 64 years) RA patients with depression (N = 647) and without depression (N = 2,015) using data from the nationally representative Medical Expenditure Panel Survey for the years 2009, 2011, 2013, and 2015. Results Overall, 25.8% had depression. In adjusted analyses, adults with RA and depression compared to those without depression were significantly more likely to have pain interference with normal work (severe pain: AOR = 2.22; 95% CI = 1.55, 3.18), functional limitations (AOR = 2.17; 95% CI = 1.61, 2.94), and lower mental health HRQoL scores. Adults with RA and depression had significantly higher annual healthcare expenditures ($14,752 versus 10,541, p < .001) and out-of-pocket spending burden. Adults with RA and depression were more likely to be unemployed and among employed adults, those with depression had a significantly higher number of missed work days annually and higher lost annual wages due to missed work days. Conclusions This study highlights the importance of effectively managing depression in routine clinical practice of RA patients to reduce pain and functional limitations, improve quality of life, and lower direct and indirect healthcare costs.

show abstract

“…There is some evidence that disease-modifying drugs used to treat RA can have spill-over effects in reducing depressive symptoms. For example, depression levels decreased significantly following commencement and continuity of rituximab, a B cell-directed therapy, among individuals with RA92 . Therefore, future studies need to systematically evaluate whether anti-rheumatic treatment among individuals with RA can help alleviate depressive symptoms.…”

mentioning

confidence: 99%

Depression, Treatment Response to TNFi, and Economic Outcomes among Working-Age Adults with Rheumatoid Arthritis

Deb¹

View full text Add to dashboard Cite

Depression is one of the most frequently occurring conditions in Rheumatoid Arthritis (RA) patients and understanding depression as a comorbidity in RA is very important. The link between RA and depression is very complex and influenced by a multitude of factors such as shared pathophysiologic pathways of inflammation, RA-related treatment response, as well as the patient's demographic and socioeconomic factors, and general difficulties in coping with the disease. Depression can increase the clinical, humanistic, and economic burden among RA patients. Growing evidence now suggests that depression is a systemic inflammatory condition and may exert a negative influence on the treatment response in RA by its effect on proinflammatory cytokines. Therefore, it is important to understand how depression is related to the treatment effectiveness of specific cytokine inhibitor drugs such as Tumor Necrosis Factor Inhibitor (TNFi) therapy that are used for the treatment of RA. The powerful anti-inflammatory effect of TNFi may have a potential beneficial effect in reducing the risk of depression in RA patients. It is important to gain a comprehensive understanding of how depression affects RA and how RA can affect depression in the real-world clinical practice settings, particularly among working-age individuals as the burden of depression is highest among working-age population. Therefore, this dissertation had three related aims focusing on working-age adults: 1) estimating the clinical, humanistic and economic burden of depression in RA; 2) examining the relationship between prevalent depression and treatment response to TNFi therapy in RA; and 3) evaluating the association between TNFi therapy and the risk of developing depression in RA. The study used data from multiple nationally representative sources to triangulate the complex relationship v Table of Contents List of Tables .

show abstract

FRI0239 Decreased prevalence of anxiety and depression in rheumatoid arthritis patients following b cell-targeted biologic therapy

Cited by 3 publications

References 0 publications

Healthcare burden of depression in adults with arthritis

Healthcare burden of depression in adults with arthritis

Burden of Depression among Working-Age Adults with Rheumatoid Arthritis

Depression, Treatment Response to TNFi, and Economic Outcomes among Working-Age Adults with Rheumatoid Arthritis

Contact Info

Product

Resources

About